Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Goserelin
Drug ID BADD_D01038
Description Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Indications and Usage Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prostate - The management of endometriosis - Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding - Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women
Marketing Status approved
ATC Code L02AE03
DrugBank ID DB00014
KEGG ID D04405
MeSH ID D017273
PubChem ID 5311128
TTD Drug ID D00BCG
NDC Product Code 55463-0005; 70720-951; 70720-950
UNII 0F65R8P09N
Synonyms Goserelin | ICI-118630 | ICI 118630 | ICI118630 | Zoladex | Goserelin Acetate | Acetate, Goserelin
Chemical Information
Molecular Formula C59H84N18O14
CAS Registry Number 65807-02-5
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C( CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C 6CCC(=O)N6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bronchial hyperreactivity22.03.01.016--Not Available
Gingival erythema07.09.13.0060.000334%Not Available
Adverse reaction08.06.01.018--Not Available
Abdominal wall haemorrhage07.16.05.002; 12.01.17.002; 24.07.02.0360.000334%Not Available
Acute kidney injury20.01.03.016--
Lower urinary tract symptoms20.02.02.023--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000667%Not Available
Administration site discomfort12.07.04.010; 08.02.04.0100.000334%Not Available
Adenocarcinoma of colon07.21.01.008; 16.13.01.0100.001135%Not Available
Bone cancer16.29.02.002; 15.09.03.0120.000501%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.000667%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.003337%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000501%Not Available
Terminal state08.01.03.0790.001168%Not Available
Metastases to thorax22.08.03.001; 16.22.02.0280.000334%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.000501%Not Available
Arterial haemorrhage24.07.01.0630.000334%Not Available
Pyelocaliectasis20.01.06.0110.000334%Not Available
Oncologic complication16.32.03.0250.000334%Not Available
Metastases to pelvis21.07.04.008; 16.22.02.021--Not Available
Exposed bone in jaw15.02.04.0340.000501%Not Available
Abdominal lymphadenopathy07.11.01.018; 01.09.01.0200.000334%Not Available
Cerebral venous sinus thrombosis24.01.04.021; 17.08.03.0060.000334%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000334%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Implant site extravasation12.07.02.042; 08.02.02.0420.001135%Not Available
Intermenstrual bleeding21.01.01.0150.000901%Not Available
Myelosuppression01.03.03.0150.000501%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 12th Page    First    Pre   12    Total 12 Pages